Unknown

Dataset Information

0

Association of Body Mass Index With 21-Gene Recurrence Score Among Women With Estrogen Receptor-Positive, ERBB2-Negative Breast Cancer.


ABSTRACT:

Importance

Body mass index (BMI) may affect the 21-gene recurrence score (RS) in patients with ER-positive, ERBB2-negative breast cancer. If high BMI increases genomic risk in ER-positive, ERBB2-negative breast cancer, weight control will become more important.

Objective

To assess the association between RS and BMI according to age groups and address BMI as a factor associated with high RS.

Design, setting, and participants

This cohort study included 2295 patients with ER-positive, ERBB2-negative breast cancer who had undergone a multigene assay between March 29, 2010, and December 31, 2020, in 2 hospitals. All of the study patients were Korean women, and the median follow-up period was 45 months (range, 1-40 months). The correlations between continuous RS and BMI were investigated. A high BMI was defined as a body mass index greater than or equal to 25. In the younger age group (age ≤45 years), a high RS was defined as an RS of greater than 20.

Exposures

Body mass index.

Main outcomes and measures

The Pearson correlation coefficient was used to estimate the association between RS and BMI. A multivariable binary logistic model was used to identify high RS.

Results

Among the 2295 women included (mean [SD] age, 49.8 [4.00] years; range, 22-81 years), 776 were aged 45 years or younger; RS and BMI were weakly correlated (correlation coefficient, 0.119; P < .001) in this younger group. Among them, the proportion of patients with an RS greater than 20 was significantly higher in the high BMI group than in the normal BMI group (45.5% [46 of 101] vs 27.3% [184 of 675]; P < .001). In the multivariable analysis, high BMI was an associated factor for high RS (odds ratio, 2.06; 95% CI, 1.28-3.32; P = .003). The 21-gene multigene assay-guided chemotherapy rate was significantly higher in patients with high BMI (30.7% [31 of 101] vs 20.2% [136 of 674]; P = .02).

Conclusions and relevance

In this cohort study of women aged 45 years or younger, high BMI was associated with higher RS in those with ER-positive, ERBB2-negative breast cancer; further studies are necessary to examine the underlying mechanisms.

SUBMITTER: Lee J 

PROVIDER: S-EPMC9706366 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Association of Body Mass Index With 21-Gene Recurrence Score Among Women With Estrogen Receptor-Positive, ERBB2-Negative Breast Cancer.

Lee Janghee J   Kim Hakyoung H   Bae Soong June SJ   Ji Jung Hwan JH   Lee Jong Won JW   Son Byung Ho BH   Ahn Sei Hyun SH   Jeong Joon J   Lee Sae Byul SB   Ahn Sung Gwe SG  

JAMA network open 20221101 11


<h4>Importance</h4>Body mass index (BMI) may affect the 21-gene recurrence score (RS) in patients with ER-positive, ERBB2-negative breast cancer. If high BMI increases genomic risk in ER-positive, ERBB2-negative breast cancer, weight control will become more important.<h4>Objective</h4>To assess the association between RS and BMI according to age groups and address BMI as a factor associated with high RS.<h4>Design, setting, and participants</h4>This cohort study included 2295 patients with ER-p  ...[more]

Similar Datasets

| S-EPMC4355173 | biostudies-literature
| S-EPMC11544499 | biostudies-literature